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Alzheimer’s disease is a progressive neurodegenerative disorder, affecting 50 million
people worldwide, for which there is no cure, or effective treatment. Individuals suffering
from Alzheimer’s show a decline in cognition over time beginning with memory loss
and ultimately leading to severe dementia, and inability to care for themselves. The
cause of Alzheimer’s is not known but likely involves a combination of genetic,
biochemical, and environmental factors. Some genes have been identified as risk factors
but monozygotic twins discordant for Alzheimer’s disease suggest other factors must
contribute to development of the disease. Investigation on epigenetic marks including
DNA methylation and post-translational modifications of histones have shown that the
patterns of these modifications change with age in the human population. Though
individuals show specific differences in epigenetic marks at the individual gene level,
there is a consistent pattern of epigenetic changes at the genome scale across the
population. Similar changes have been identified in patients with Alzheimer’s disease,
though these occur at an earlier age compared to healthy individuals. The early cognitive
impairment in Alzheimer’s disease can be mistaken for premature ageing correlating
with the timing of epigenetic changes occurring at a younger age in individuals with
Alzheimer’s. Such observations suggest that the epigenetic changes may contribute to
disease pathology. Exactly how epigenetic modifications contribute to specific aspects
of Alzheimer’s disease is the focus of many researcher groups across the world.
A number of drugs are available that inhibit the enzymes that modify chromatin and
change the epigenetic landscape of the genome. Therefore, an understanding of the role
of chromatin modifications in Alzheimer’s could offer an opportunity for novel therapeutic
strategies. Research using animal models of Alzheimer’s suggests that the epigenetic
changes in Alzheimer’s disease may have a profound impact on cognition and underlie
cognitive impairment while there is no clear evidence that they might contribute directly
to neuronal loss.
Keywords: chromatin, epigenetics, Alzheimer’s, dementia, methylation, acetylation, ageing, histone
Abbreviations: AD, Alzheimer’s disease; BET, bromodomain and extra-terminal; HDAC, histone deacetylase;
SAM, S-adenosylmethionine; SAHA, suberanilohydroxamic acid.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder and the most common form of dementia, affecting
over 50 million people worldwide (Prince et al., 2015). The
disease is characterised by memory loss, difficulties with
communication and a loss of orientation, thought to be driven
by neurodegeneration resulting from a build-up of extracellular
amyloid plaques, and intracellular neurofibrillary tangles of
hyperphosphorylated Tau protein. Individuals with AD show a
progressive degeneration of cognitive function for which there
is currently no cure or effective treatment and is ultimately
fatal. AD is the third major cause of death in the developed
world and it is predicted to cost the world economy $1trillion
in 2018 (Prince et al., 2015). Although the cause of AD is
not known, the most favoured hypothesis over the last 25
years has been the amyloid cascade hypothesis proposed in
1991, which suggested that inappropriate processing of the
amyloid-β precursor leads to the build-up of amyloid plaques,
formation of Tau tangles, and neuronal death (Hardy and
Allsop, 1991). Though the amyloid hypothesis has provided
biochemical targets for clinical intervention there is yet to be
a therapeutically useful drug developed and, more recently,
alternative hypotheses have been proposed [for a current
overview see (Karran and De Strooper, 2016; Behl and Ziegler,
2017)]. Such hypotheses include; mitochondrial dysfunction,
reduced glucose metabolism, cell cycle re-entry brought about
by chemical stressors, reduced vasculature in the brain, and
production of toxic oligomeric amyloid-β and the involvement of
aberrant protein phosphorylation (Karran and De Strooper, 2016;
Oliveira et al., 2017). There is not one single cause responsible
for all cases of AD and AD can be divided into sporadic and
familial cases. Familial AD is generally characterised by early
onset (younger than 65 years) and associated with mutations
in genes including; amyloid precursor protein (APP), presenilin
(PSEN) 1, and PSEN2 (Bekris et al., 2010). Mutations in other
genes such as Apolipoprotein E (APOE) and tau (MAPT) are
associated with increased risk of sporadic, late onset AD though
they not on their own sufficient to cause the disease (Coon et al.,
2007; Allen et al., 2014). Monozygotic twins with discordance for
AD suggest other factors, perhaps epigenetic mechanisms make
significant contributions to disease pathology (Mastroeni et al.,
2009).
Age is the biggest risk factor for AD and many epigenetic
changes occur with normal ageing (Hernandez et al., 2011; Heyn
et al., 2012). These changes are also seen in AD though they
occur at an earlier age in Alzheimer’s patients (Wang et al., 2008;
Chouliaras et al., 2013b) and AD can be mistaken for premature
ageing (Burns and Iliffe, 2009). How these epigenetic changes
contribute to the pathology and development of Alzheimer’s is
currently of great interest.
The term epigenetics was coined by Conrad Waddington
in 1942 (Waddington, 2012) in his description of development
pathways of cells and the inheritance of acquired characteristics
during cell division toward specialisation. Since that time, the
phrase has been used in many different ways and many of
the alternative definitions for it have been nicely summarised
(Greally, 2018). One popular use of the word epigenetics, that will
be used here, is for the description of modifications of DNA, such
as cytosine methylation, and post-translational modifications of
histones, such as acetylation, that provide long lasting changes to
cells, and influence their homeostasis even in the absence of the
original perturbation that generated them.
DNA METHYLATION CHANGES
ASSOCIATED WITH ALZHEIMER’S
DISEASE
The first identified, and most widely studied, epigenetic
modification is DNA methylation. Cytosine residues on both
strands, mostly within CpG dinucleotide sequences, can be
methylated. This methylation contributes to gene regulation by
acting as binding sites for proteins containing methyl cytosine
binding domains that influence local chromatin structure. Once
deposited, methylation patterns are maintained through cell
division by DNA methyltransferase enzymes that methylate the
hemi-methylated DNA in daughter cells. DNA methylation was,
for a long time, considered to be irreversible and only subject
to removal through the inhibition of re-deposition upon cell
division. More recently a number of labs provided evidence
that DNA methylation can be actively removed and that this
removal plays a significant role in the function of the nervous
system [reviewed in (Wu and Zhang, 2010)]. Compared to age-
matched controls, individuals with Alzheimer’s show an overall
global hypomethylation (Mastroeni et al., 2010; Chouliaras et al.,
2013a) over the entire genome but hypermethylation of a number
of specific genes (Wang et al., 2008). These differences reflect
the changes associated with normal ageing (Fuke et al., 2004;
Rakyan et al., 2010; Hernandez et al., 2011; Heyn et al., 2012)
and is one piece of evidence supporting the idea that AD may, at
least in part, be brought about by an accelerated ageing process.
During the human lifespan, patterns of DNA methylation diverge
over time between individuals, most convincingly demonstrated
in monozygotic twins (Fraga et al., 2005; Talens et al., 2012).
However, within older individuals (>75 years) patterns of DNA
methylation appear to converge and undergo an age-dependent
dedifferentiation demonstrated by a reduction in variation
between tissues and specific brain regions, such as the cortex and
cerebellum (Oh et al., 2016). This loss of variation in methylation
is not the result of altered cell composition within tissues and
appears more pronounced in individuals with Alzheimer’s (Oh
et al., 2016).
Perturbation in normal DNA methylation can be brought
about as a result of altered one-carbon methylation metabolism,
resulting in altered levels of plasma homocysteine. Such altered
one carbon methylation is associated with AD (Ho et al., 2011),
although whether it contributes to pathology or is a marker is
unclear (Seshadri, 2006; Troesch et al., 2016). The source of
the methyl group added to DNA is the methyl donor, SAM,
though SAM is also utilised in a number of other pathways and
is a major cellular antioxidant. Excessive requirements in other
pathways for example in response to oxidative stress has the
potential to reduce the levels of SAM, and its availability for DNA
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methylation reactions. The global hypomethylation associated
with Alzheimer’s is consistent with the lower levels of SAM seen
in the brains of patients with Alzheimer’s (Morrison et al., 1996).
Evidence that reduced one-carbon metabolism precedes changes
in DNA methylation comes from animal models of Alzheimer’s
fed a reduced vitamin B diet to reduce circulating levels of SAM.
TgCRND8 mice (a mouse model of AD, Table 11) on this diet
show reduced DNA methyltransferase activity, hypomethylation
of the Psen1 promoter, increased PSEN1 expression, and
increased level of amyloid plaques (Fuso et al., 2008; Fuso et al.,
2011). Supplementing with SAM reduced expression of Psen1 and
Bace1 in the TgCRND8 mice, and the development of amyloid
plaques was decreased (Fuso et al., 2012; Cavallaro et al., 2017).
Together, these data provide solid support for the idea that an
imbalance in one-carbon metabolism results in reduced DNA
methylation at the Psen1 gene, increasing PSEN1 expression and
activity, and contributes to the build-up of amyloid deposits.
These data implicate the involvement of a single gene, although
many other changes in DNA methylation are also likely to be
1 A number of mouse models have been developed to provide an in vivo model
of Alzheimer’s disease that replicates the condition seen in humans. None of the
models replicates all features of Alzheimer’s seen in humans and many drugs that
show efficacy within these models have been found to be less efficacious in human
patients. A list of the models discussed in this review, the genetic basis of the model,
and their origin are given in Table 1.
present in these animals that may contribute to the increase in
plaque load. Indeed, specific differences in DNA methylation
have been observed between individuals with Alzheimer’s and
age-matched healthy controls at number of genes associated with
Alzheimer’s, including PSEN1, APOE, MTHFR, DNMT1, (Wang
et al., 2008). The epigenetic drift that is observed during ageing
may predispose individuals to the development of Alzheimer’s if
it occurs more rapidly in some individuals or if specific genes are
more susceptible to changes. Certainly epigenetic changes that
influence expression of genes such as DNMT1, whose function
is to regulate epigenetic marks, will likely result in a positive
feedback loop, and an accelerated divergence from a normal
ageing profile.
In addition to methylation, cytosines are also found
hydroxymethylated (Kriaucionis and Heintz, 2009), though the
level of hydroxymethylated cytosines are a small fraction of total
cytosines (approx. 0.1–2%) and they were originally proposed to
be an intermediate step toward DNA demethylation. Whether
hydroxymethylated cytosines are an intermediate or act as a
specific marker in their own right is still not certain. However,
it is clear that their number increases in the brain during
ageing and a gene ontology analysis uncovers an association of
the genes showing hydroxymethylation with neurodegenerative
disorders (Song et al., 2011). In a study of twins in which
one twin suffered with AD while the other did not, lower
TABLE 1 | Mouse models of Alzheimer’s disease.
Mouse model Synonym Genetic change Link to AD Consequence of change Reference
Tg2576 APP KM670/671NL The APP KM670/671NL mutation
was found to be linked to AD in 2
large Swedish families
Results in an increase in Aβ40
and Aβ42 levels and mice
develop amyloid pathology
Hsiao et al., 1996
APP/PS1 PS/APP APP KM670/671NL,
PSEN1 M146V
The PSEN1 M146V mutations has
been found in a number of families
and associated with AD
The PSEN1 M146V mutation
results in reduced
carboxypepdtidase γ-cleavage
activity of PSEN1 and leads to
increased levels of Aβ42
Holcomb et al., 1998
3xTg AD APP KM670/671NL, MAPT
P301L, and PSEN1 M146V
The MAPT P301L mutation has been
found in 32 families around the world
and is associated with
fronto-temporal dementia and
parkinsonism
The MAPT P301L mutation
increases the aggregation rate of
tau protein by promoting the
formation of paired helical
filaments
Oddo et al., 2003
CK-p25 Overexpression of p25 in
postnatal forebrain
p25 stimulates CDK5 activity and
aberrant CDK5 activity has been
associated a number of
neurodegenerative diseases. It is not
clear if p25 expression is actually
increased in individuals with AD
P25 is an activator of CDK5 and
ectopic expression of p25 in
neurons results in enhanced
CDK5 activity
Cruz et al., 2003
APPswe/
PSEN1dE9
APP/PS1 APP KM670/671NL,
PSEN1dE9
The PSEN1dE9 mutation is found in
AD patients that show large amyloid
deposits and an absence of more
typical dense amyloid deposits
The PSEN1de9 mutation results
in increased amyloid deposition
and an increase in the levels of
Aβ42
Jankowsky et al., 2004
APPPS1-21 APP KM670/671NL and
PSEN1 L166P
The PSEN1 L166P has been
identified in a single family and
associated with very early onset of AD
There is increased amyloid
burden in mice at 6 months
Radde et al., 2006
TgCRND8 APP KM670/671NL, V717F The V717F mutation has been found
in a number of families and
associated with early onset AD
Results in an increase in Aβ40
and Aβ42 levels and mice
develop amyloid pathology.
Chishti et al., 2001
The table identifies the different genetic changes used to develop mouse models of AD, how these mutations are linked to AD and what changes have been observed to
occur in the mice as a consequence of the mutations.
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levels of hydroxymethylated cytosine were found in both glia
and neurones in the post-mortem brain of the AD sufferer
(Chouliaras et al., 2013a). Consistent with other studies, the
brain from the individual with AD also showed reduced levels
of methyl cytosine. A second piece of evidence supporting the
association of hydroymethylation and AD is the finding that
a SNP within the gene encoding Ten-Eleven Translocation-
1 (TET1, which catalyses the conversion of 5-methylcytosine
to 5-hydroxymethylcytosine) is associated with late onset AD
(Morgan et al., 2008). The SNP itself is in an exon but does not
result in an altered protein coding sequence, and it is unknown
whether the effect may impact positively, or negatively on either
function, or expression.
Changes in DNA methylation may be important for the
cognitive symptoms associated with Alzheimer’s rather than
the neuronal loss. Aged mice show reduced levels of mRNA
expression of the DNA methyltransferase DNMT3a2 which may
underlie the reduced level of DNA methylation in older animals
(Oliveira et al., 2012). Ectopic expression of DNMT3a2 in the
brains of old mice using viral delivery increased their cognitive
performance in fear conditioning and object-place recognition
tasks. Additionally, reducing the level of DNMT3a2 using shRNA
in younger mice reduced their performance across the same tests
(Oliveira et al., 2012). Genetic association studies have identified
SNPs in DNMT3A associated with mild cognitive impairment
(Chouliaras et al., 2015), and aged mice show a reduction in
the density of DNMT3 positive cells within the hippocampus
as assessed by immunohistochemistry (Chouliaras et al., 2011).
Where other DNMT family members have been interrogated for
their association with Alzheimer’s, DNMT1 did not show any
association, while DNMT3B was found to be associated with
Alzheimer’s in one study (Pezzi et al., 2014) though not in another
(Coppede et al., 2012).
In summary the general picture emerging is that patterns
of global DNA methylation show consistent changes with
age and these changes appear to occur earlier in individuals
with Alzheimer’s. To date there is little evidence that DNA
methylation changes are responsible for the neuronal loss seen in
AD, although given the fact changes in DNA methylation result
in significant gene expression changes, it is not unreasonable to
expect some impact on neuronal cell survival. There is however,
substantial evidence that DNA methylation/demethylation plays
a key role in cognition and experimental evidence demonstrating
that altering the enzymes that modify methylation can have
effects on learning and memory. Thus, it would seem that the
DNA methylation changes associated with Alzheimer’s most
likely contribute toward the cognitive deficits in individuals
though this may be manifest in several ways for example altered
expression of specific genes as well as a reduction in the ability
to dynamically add and remove methylation. Therapeutically
inhibiting these enzymes may provide some benefit and allow
restoration of more normal levels of methylation. Increased
DNA methylation is associated with many cancers and inhibitors
of DNA methylation have been investigated as treatments
for some cancers (reviewed in Nervi et al., 2015; Zahnow
et al., 2016). A number of clinically tested DNA methylation
inhibitors exist including Vidaza (5-azacytidine), Decabitine
(5-aza-2′-deoxycytidine), Zebularine (1-(β-D-ribofuranosyl)-
2(1H)-pyrimidinone) and Apresoline (Hydralazine), and there
is some evidence to support efficacy of these drugs as cancer
treatments. However, most trials have used these in combination
with other anti-cancer therapies and some of these drugs
are believed to work through their incorporation into newly
synthesised DNA so while they may be effective in highly
proliferative cancer cells they would be less useful in non-
proliferative neurones. Toxicity appears favourable and even in
combination with the histone deacetylase (HDAC) inhibitor,
valproic acid, 5-azacytidine was well tolerated with no significant
adverse effects in humans (Braiteh et al., 2008). The next step
would be to characterise effectiveness of these inhibitors to
improve cognition and monitor the longer term effects they may
have within the nervous system.
HISTONE ACETYLATION IS
DEREGULATED IN ALZHEIMER’S
DISEASE AND NEGATIVELY IMPACTS
UPON MEMORY
As well as modifications to DNA, histone proteins can be
posttranslationally modified at specific residues leading to a
change in the level of gene expression. This is brought about
by an alteration of chromatin structure and/or recruitment of
specific proteins to these epigenetic marks. One of the earliest
modifications identified to occur on histones is the acetylation of
lysine residues which is deposited by enzymes known as histone
acetyltransferases (HAT) and removed by HDACs. Acetylation
of histones is generally associated with active gene transcription.
A number of studies have identified an important role for
histone acetylation in normal ageing and in cognitive function.
In aged mice, reduced memory performance has been seen to be
associated with a reduction in histone acetylation levels (Peleg
et al., 2010). In young mice, learning was associated with an
increase of Histone H4 lysine 12 (H4K12) acetylation at genes
whose expression was increased. By contrast, older (16 month)
mice showed a lack of H4K12 acetylation and little change in gene
expression. Treatment with the HDAC inhibitor SAHA was able
to enhance fear conditioning induced gene expression changes
and restore learning in aged mice, by promoting increases in
acetylation. Aged mice also show an increased expression of
HDAC2 within the hippocampus and this is thought to be
associated with the normal ageing process as it can be attenuated
by calorific restriction (Chouliaras et al., 2013b).
There is a wealth of evidence that links protein acetylation
to AD and suggests that such changes in acetylation play
an important role in underlying the cognitive deficits seen
in patients. In brain sections from post-mortem samples of
Alzheimer’s sufferers, both HDAC2 and HDAC6 show increased
levels (Ding et al., 2008; Graff et al., 2012) though a separate
report suggested reduced HDAC2, and HDAC1 levels (Mastroeni
et al., 2010). The only study looking at histone acetylation
levels in post-mortem brains suggested that these are higher
in patients with Alzheimer’s than in age-matched controls
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(Lithner et al., 2013). A more consistent pattern has emerged in
animal models of Alzheimer’s. Mouse models of Alzheimer’s
show the same baseline of histone acetylation as wild type animals
but a blunted increase in acetylation levels in response to fear
conditioning (Francis et al., 2009). Several studies have also
shown that HDAC inhibitors can reduce memory impairments
in a number of different mouse models of Alzheimer’s. Sodium
butyrate, sodium valproate and SAHA all restored contextual
fear memory in APPswe/PS1de9 mice (Table 1), and increased
the acetylation levels of histones in the hippocampus (Kilgore
et al., 2010). A 6 week treatment of sodium butyrate to 14 month
old APPPS1-21 mice (Table 1) resulted in increased histone
acetylation levels in the hippocampus, increased expression
of a number of genes involved with synaptic transmission
and the mice also demonstrated improved associative memory
(Govindarajan et al., 2011). Phenylbutrate treatment restored
deficits in contextual fear conditioning for Tg2576 mice
(Table 1) and this was associated with increased spine density
in hippocampal neurones, reduced levels of amyloid-β and
increased expression of genes involved in synaptic plasticity
(Ricobaraza et al., 2011). The HDAC inhibitor, W2, improved
performance in the Morris water maze, decreased amyloid-β
levels, and also increased expression of the amyloid-β degrading
enzyme MMP2 in 3xTg AD mice (Sung et al., 2013). Together
these data suggest that HDAC inhibitors have potential utility to
reduce cognitive deficits associated with Alzheimer’s. However,
the lack of selective HDAC inhibitors and a comprehensive
knowledge of their target proteins has precluded a thorough
understanding of their mechanism of action.
The Alzheimer mouse model, CK-p25 (Table 1), in which
p25 is over expressed in neurones, shows many hall marks of
Alzheimer’s including neuronal loss, amyloid-β accumulation
and memory deficits (Cruz et al., 2003). These mice show
increased expression of Hdac2 (but not Hdac1 or 3) (Graff et al.,
2012). This increase in HDAC2 protein resulted in increased
levels of HDAC2 at a number of genes important in synaptic
function, a reduction in the level of histone H4 acetylation at their
promoters, and reduced expression of their mRNAs. Knockdown
of HDAC2 protein using shRNA was able to restore both histone
acetylation and gene expression levels identifying it as a causative
agent for these effects. The CK-p25 mice also show a reduction in
the density of synapses in the hippocampus and behaviourally,
a reduced performance in contextual fear conditioning, and
the Morris water maze compared to control animals. Both the
synaptic density and the performance in the memory tasks is
improved once HDAC2 is knocked down, providing compelling
evidence that HDAC2 levels are functionally important (Graff
et al., 2012). Interestingly, knockdown of HDAC2 was not
associated with an increase in neuronal number, suggesting that
the increase in synaptic density and cognitive improvement do
not require production of new neurones to replace those that
were lost (Graff et al., 2012). Knockdown of HDAC2 was also
shown to improve memory in APPswe/PSEN1dE9 mice and this
was correlated with increased histone acetylation at the Bdnf
gene and increased Bdnf mRNA (Hsiao et al., 2017). Many
strategies aimed at treating Alzheimer’s are based around either
prevention of neuronal loss or replacement of those neurones that
have been lost. These data suggest that modulating the neurones
that remain could provide a therapeutic benefit to individuals
with Alzheimer’s. In humans, HDAC2 protein levels are found
at higher levels in post-mortem brain tissue from patients who
suffered with Alzheimer’s compared to age-matched controls
suggesting that targeting HDAC2 may be therapeutically useful
(Graff et al., 2012).
Alongside the evidence that increased HDAC2 levels
contribute to Alzheimer’s there is also substantial evidence
that modulating HDAC2 levels has a direct effect on cognitive
ability (Guan et al., 2009; Morris et al., 2013). Transgenic
mice with increased expression of HDAC2, but not HDAC1,
in neurones show a reduced performance in conditioned fear
response and the Morris water maze (Guan et al., 2009). HDAC2
overexpression does not result in any obvious brain morphology
deficiencies by 6 months, suggesting that increased HDAC2 alone
does not lead to AD (Guan et al., 2009). The loss in cognitive
performance resulting from increased HDAC2 correlated with
a reduced density of dendritic spines of hippocampal CA1
pyramidal neurones and reduced LTP within the hippocampus.
Interestingly, mice lacking HDAC2 showed a higher density of
spines from equivalent neurones, enhanced performance in the
memory tasks, and increased synaptic plasticity demonstrated
by more easily induced LTP (Guan et al., 2009). Lack of HDAC2
in adult forebrain neurones is associated with an improved
performance in associative memory tasks and enhanced LTP
in hippocampal neurones (Morris et al., 2013). Together
these data suggest that inhibition of HDAC2 in patients
with Alzheimer’s may be able to compensate for some of the
cognitive deficits, but would probably have little effect on the
neurodegeneration associated with Alzheimer’s. Nevertheless,
providing cognitive improvements to individuals would provide
significant enhancements to their quality of life. The mechanism
by which HDAC2 negatively regulates synaptic plasticity and
memory is unknown but might involve its interaction with the
transcription factor Sp3 (Yamakawa et al., 2017). Like HDAC2,
Sp3 is elevated in the hippocampus of post-mortem brains from
Alzheimer’s patients, and is also upregulated in the CK-p25 AD
mouse model (Yamakawa et al., 2017). Knockdown of Sp3 using
shRNA in CK-p25 mice was sufficient to increase excitatory
postsynaptic currents in neurones, restore expression levels of
repressed genes, and enhance LTP. Evidence that a HDAC2:Sp3
complex is important for these features was provided by the
observation that expression of a C-terminal region of HDAC2,
that interacts with Sp3 and thus disrupt the endogenous
HDAC2:Sp3 complex, was able to mimic the effects seen with
either Sp3, or HDAC2 knockdown (Yamakawa et al., 2017). Use
of this C-terminus of HDAC2 as a therapeutic agent would be
quite challenging given its large size, though its effectiveness
in animal models should provide enough preliminary evidence
to encourage the development of a small molecule that could
interfere with the HDAC2:Sp3 interaction and equally provide
potential benefit to human patients.
Evidence that the increased levels of another HADC family
member, HDAC6, seen in patients with Alzheimer’s contributes
to disease pathology was highlighted by Govindarajan et al.
(2013). Knockout of Hdac6 in the APPPS1-21 mouse (Table 1)
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rescued impaired freezing behaviour and improved performance
in the Morris water maze suggesting that removal of Hdac6
was sufficient to restore associative and spatial memory. Unlike
HDAC2, HDAC6 is found in the cytoplasm and its most
recognised target protein is tubulin (Zhang et al., 2003),
though it can also deacetylate Tau and Prx1 (Cook et al.,
2014; Carlomagno et al., 2017). Deacetylation of Tau increases
its potential to be phosphorylated and potentially contributes
to aggregation (Carlomagno et al., 2017) while deacetylation
of Prx1 reduces it anti-oxidant activities (Choi et al., 2017).
A number of independent studies highlight increased HDAC6
expression associated with Alzheimer’s and inhibition of HDAC6
as potentially beneficial, though the evidence would suggest that
the important proteins regulated by HDAC6 are not localised to
the nucleus and therefore not directly involved in regulating gene
expression. Additionally many of the HDAC inhibitors that have
been shown to improve cognition in Alzheimer’s mouse models
do not effectively inhibit HDAC6, indicating that they must be
providing their beneficial effects via an alternative HDAC, most
likely HDAC2.
Levels of protein acetylation are regulated not just by
removal via deacetylases but also by addition via acetylases.
In complimentary studies to those identifying increased HDAC
levels, reduced levels of the histone acetyltransferase CREB-
binding protein (CBP) were observed in APPswe/PSEN1dE9
mice (Table 1) at an age of 3 months, preceding the development
of Alzheimer’s like symptoms, and this was associated with
reduced histone acetylation levels in the hippocampus (Ettcheto
et al., 2017). Additionally ectopic expression of CBP in 3xTg
AD mice using lentiviral delivery enhanced performance of these
mice in the Morris water maze (Caccamo et al., 2010). Thus it
would appear that shifting of the acetylation equilibrium toward
the non-acetylated state has a negative impact on cognitive
function, though there is no suggestion that it plays any
significant role in cell survival and most likely does not directly
contribute to neuronal loss in AD.
Global inhibition of HDAC activity in the brain is unlikely
to provide long term benefits, as activity of some deacetylase
enzymes have been positively correlated with neuronal survival
and/or cognition. Evidence has implicated a role for HDAC1
in facilitating DNA damage repair (Kim et al., 2008; Dobbin
et al., 2013; Wang et al., 2013). In CK-p25 mice, p25 can
interact with HDAC1 and inhibit its recruitment to chromatin
and its repressor activity (Kim et al., 2008). Specific knockdown
of HDAC1 or inhibition of HDACs with MS-275 led to DNA
damage and neuronal death of primary cortical neurones while
ectopic expression of an enzymatically active form of HDAC1,
but not HDAC2, was able to rescue p25 induced cell death (Kim
et al., 2008). HDAC1 facilitates DNA repair via its interaction
with an NAD-dependant deacetylase, SIRT1 (Dobbin et al., 2013).
HDAC1 itself is acetylated, on a lysine residue at amino acid
position 432, which causes a reduction in HDAC1 activity, and
this acetyl mark is removed by SIRT1. Treatment of CK-p25 mice
with activators of SIRT1 results in deacetylation of HDAC1 and
a reduction in DNA damage as assessed by lower numbers of
γH2AX positive cells (Dobbin et al., 2013). HDAC1 and HDAC2
are structurally very similar and there are currently no inhibitors
selective for one over the other. Thus any potential benefits
in using a HDAC inhibitor to inhibit HDAC2 may be counter
balanced by the detrimental effects of the inhibition of HDAC1.
Unlike Class I HDACs (1, 2, 3, and 8), which are expressed
in the nucleus, class II HDACs shuttle between the nucleus and
cytoplasm. In neurones, HDAC5 functions in the nucleus to
repress gene expression, and is inactivated by exportation from
the nucleus in response to activation of a calcium signalling
pathway driven by neuronal activity (Chawla et al., 2003).
Knockout of HDAC5 in the APPPS1-21 mouse (Table 1) model
did not produce an improvement in memory in either fear
conditioning or performance in the Morris water maze (Agis-
Balboa et al., 2013). The result of HDAC5 knockout in wild type
mice is not clear as one group identified reduced performance
in a Morris water maze by Hdac5 knockout mice (Agis-Balboa
et al., 2013) while another group reported that Hdac5 knockout
had no effect on context dependent fear memory (Kim et al.,
2012). Knockout of another class II HDAC, Hdac4, specifically
in forebrain neurones resulted in reduced synaptic plasticity, and
impaired performance in context dependent memory tasks (Kim
et al., 2012). Haploinsufficiency of HDAC4 is also associated with
mental retardation in humans (Williams et al., 2010) suggesting
that the roles identified for HDAC4 in mice are likely conserved
in humans.
However, increasing histone acetylation levels globally may
also have some negative consequences with respect to proteins
that recognise and interact with acetylated lysine. Acetylated
histones provide binding sites for specific proteins that contain
a binding motif known as a bromodomain (Dhalluin et al.,
1999). One set of proteins known to bind chromatin via an
interaction of such a domain with acetylated histones are the
BET proteins (Padmanabhan et al., 2016). JQ1 is a small molecule
able to block the binding of these proteins to chromatin, and can
improve associative memory in the APPS1-21 transgenic mice,
as well as enhance LTP of hippocampal neurones (Benito et al.,
2017). Treatment of mice with JQ1, globally or specifically in
the brain, immediately following a fear conditioning protocol
resulted in increased freezing behaviour at 24 h and 4 weeks
after training, and enhanced performance in the Morris water
maze. Associated with the improved memory was an increase in
LTP of hippocampal slices treated with JQ1 (Benito et al., 2017).
Interestingly JQ1 was able to restore memory and LTP levels in
the APPS1-21 mice to those seen in wild type control animals,
and was also able to enhance both memory and LTP when tested
in wild type mice (Benito et al., 2017). Another study, however,
showed a lack of effect on response to a fear conditioning
stimulus in wild type mice receiving a 3 week treatment of
JQ1 and showed evidence that memory consolidation was
negatively affected (Korb et al., 2015). Such apparent differences
may be the result of different conditioning paradigms. As we
already know that memory formation and recall is a complex
process, such apparently conflicting data in the literature is not
surprising. Perhaps more focus on the AD model is warranted
rather than examination of the effects on wild type animals.
Treatment of APPS1-21 mice with JQ1 was also shown to change
the expression of a number of genes important for synaptic
function, although it is unclear which of these are important
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and whether these changes are the result of inhibition of BET
protein interaction with acetylated histones or other acetylated
proteins. By contrast wild type animals showed fewer changes
in gene expression in response to JQ1. This pattern of response
is mimicked by treatment with HDAC inhibitors and has led to
the suggestion that the chromatin state in Alzheimer’s becomes
deregulated and thus much more amenable to the influence of
external factors (Fischer, 2014).
Inhibitors of both BET and HDAC are of interest, like
DNA methylation inhibitors, for their potential as anti-cancer
therapies. There has been no evidence so far that HDAC, or BET
inhibitors can reduce, or stop the ongoing neurodegeneration
in Alzheimer’s, though their effectiveness at improving cognitive
ability after the onset of disease pathology does show promise
for reducing some of the more tragic consequences of AD.
Targeting acetylation globally with HDAC inhibitors is likely to
have significant deleterious effects due to the positive roles of
some HDAC enzymes in DNA damage repair, as well as learning,
and memory. Despite an often cited need for more selective or
specific HDAC inhibitors, none have yet emerged. The similarity
of the structures of the active site within HDAC enzymes would
suggest that traditional small molecule type drugs would not be
able to interact one active site but be excluded from another.
Differences in function between the HDAC family members
are brought about by their interaction with different proteins
and an approach aimed at inhibiting these interactions might
prove more rewarding and more amenable to produce selective
inhibitors. However, inhibiting protein:protein interactions is
challenging and brings a different set of hurdles to overcome
before success can be made. A combination of HDAC and DNA
methylation inhibition has been trialed in cancer (Braiteh et al.,
2008) and may be warranted as a potential treatment of AD.
The major advantage of HDAC inhibition over inhibition of
DNA methylation is that we know HDAC inhibitors can increase
cognitive ability in mouse models of AD over the short term.
The barrier to overcome with HDAC inhibition is likely to be the
lack of compounds that can selectively inhibit one member of the
HDAC family without interfering with the others.
INCREASED HISTONE METHYLATION
NEGATIVELY IMPACTS ON COGNITIVE
FUNCTION IN ALZHEIMER’S
The other major post-translational modification that is present
on histones is methylation. Both lysine and arginine amino acids
can be methylated and several forms of methylated residues
exist including mono-, di- or tri- methylated lysines and mono-,
symmetrically di-, and asymmetrically di-methylated arginines
(Di Lorenzo and Bedford, 2011). Unlike acetylation, methylation
can have positive or negative effects on transcription depending
on which residue is methylated. For example methylation of
Histone H3 lysine 4 (H3K4) is associated with gene expression
(Santos-Rosa et al., 2002) while methylation of H3K9 and H3K27
is associated with gene repression (Rea et al., 2000; Kuzmichev
et al., 2002). Very few studies have so far investigated a potential
role for histone methylation in the pathology of AD and most
of what we can surmise about their role in Alzheimer’s pathology
has been determined using cultured neurones or other cells. Some
analysis has been performed in mouse models and it is suggested
that Tg2576 mice (Table 1) show increased levels of dimethylated
H3K9 (H3K9Me2) in both the cortex and hippocampus by 3
months of age (Lithner et al., 2013). However, in the same study,
they also appear to show an increase in acetylation of H3 and
reduced levels of total histone protein in relation to the total
cellular protein, which may skew the apparent differences as
these were used for normalisation (Lithner et al., 2013). Exposure
of cortical and hippocampal neurones to hypoxia resulted in
an increase in H3K9Me2 and decrease in H3 acetylation in
the Neprilysin promoter (Wang et al., 2011). Neprilysin is the
enzyme that degrades amyloid-β peptide, regulating its levels, and
reduced Neprilysn is associated with increased amyloid-β (Marr
et al., 2004). The increased H3K9Me2 levels are mostly likely
brought about as a result of increased levels of the major histone
methyltransferse which deposits this mark, G9a. Knockdown of
G9a using siRNA caused a reduction in H3K9Me2 though was
not sufficient on its own to restore NEP gene expression (Wang
et al., 2011). If increased activity of G9a has a contributory role in
AD then G9a inhibitors could have some utility in its treatment.
Drugs that inhibit G9a have been identified and one, diazepin-
quinazolin-amine derivative (BIX-01294) shows specificity for
G9a over other methyltransferases (Kubicek et al., 2007), is
able to modulate H3K9Me2 levels in mammalian cells, induces
autophagy in a number of tumour cell lines (Ciechomska et al.,
2016), and reduces tumour growth in a mouse model (Ke et al.,
2014). Perhaps most encouragingly, treatment with BIX-0294 was
able to restore synaptic plasticity that had been impaired in rat
hippocampal slices by amyloid-β 1-42 oligomers (Sharma et al.,
2017). Thus G9a inhibition may be one way to counter synaptic
plasticity deficits thought to be associated with AD and thus
improve patient cognition.
Histone methylation also occurs at H3K4, in this case
associated with increased gene expression. Induction of p25
expression in the CK-p25 mouse results in increased tri-
methylated H3K4 (H3K4Me3) at 3,667 promoter regions
and decreased H3K4Me3 at 5,056 promoter regions, with
corresponding increased and decreased expression of the
associated genes (Gjoneska et al., 2015). This data was collected
from homogenised hippocampal tissue and not all cells may
respond in the same way, for example increased H3K4Me3
present at some genes may occur in different cells to the
decreased H3K4Me3 present at others. Indeed, the promoters
showing increased H3K4Me3 are linked to genes associated
with immune function, suggesting a microglial origin while
the promoters showing decreased H3K4Me3 are linked to
genes associated with neurodevelopment suggesting a neuronal
origin. Consistent with this idea, forebrain specific loss of the
methyltransferase enzyme KMT2A, which adds H3K4Me3 to
histone proteins, results in reduced expression of a similar
set of genes to that seen in CK-p25 mice (Kerimoglu et al.,
2017). Loss of KMT2A in forebrain neurones also resulted in
reduced fear conditioning and impaired spatial memory in the
Morris water maze (Kerimoglu et al., 2017). The gene targets
of the enzyme included those involved with transcriptional
Frontiers in Neuroscience | www.frontiersin.org 7 September 2018 | Volume 12 | Article 649
fnins-12-00649 September 17, 2018 Time: 16:40 # 8
Wood Epigenetic Modifications in Alzheimer’s Disease
regulation, chromatin binding and mRNA processing, reduction
in expression of which is likely to have broad effects on cellular
physiology. Overall, the behavioural phenotype of mice lacking
KMT2a is very similar to that of the CK-p25 mice used as a model
of Alzheimer’s, though the pathology is different as KMT2A
knockdown does not result in the associated neurodegeneration.
These data do provide some suggestions that a reduction in
H3K4Me3 in neurones contributes to the cognitive decline
in Alzheimer’s, while increased H3K4Me3 in microglia or
other immune cells may contribute to the neuro-inflammatory
response. Therapeutically, enhancing KMT2a activity would be
challenging, although inhibiting the opposing enzymatic activity,
H3K4Me demethylase, would be tractable, and could achieve the
same objective of increased H3K4Me in neurones. A number
of demethylases have been identified that target H3K4Me3
including KDM2B (Fbxl10, Janzer et al., 2012) and the KDM5A-
D family (JARID1-4, Secombe and Eisenman, 2007) and selective
inhibitors to them have been identified (Rotili and Mattevi, 2016).
CONCLUSION AND FUTURE
PERSPECTIVE
In summary, individuals with AD display a host of epigenetic
differences compared to healthy age-matched individuals. These
chromatin changes are also associated with normal ageing
and give support to the idea that AD is at least partly
a manifestation of a faster ageing process. The changes in
chromatin marks associated with Alzheimer’s appear to have
a demonstrable negative impact on cognitive function, but
any direct contribution to neurodegeneration itself has not
been well established. Treatments or other strategies that
target the enzymes regulating these chromatin marks have
been shown to have beneficial effects on cognition in mouse
models of Alzheimer’s, without altering neuronal survival.
Previous strategies for the treatment of Alzheimer’s have focused
on the clearance of amyloid-β deposits, reduction of the
hyperphosphorylated Tau, and inhibition of neuronal death
and/or replacement of lost neurones. However, even after some
success in animal models, none of these approaches have proven
to be a successful strategy for treating AD in humans. Approaches
to influence the deposition or removal of specific chromatin
marks represent so far untried strategies, which might be
expected to provide cognitive benefits and at least improve the
quality of life for Alzheimer’s sufferers. However, with continued
neuronal loss, such treatments would be expected to lose efficacy
over time, so perhaps a dual strategy targeting chromatin changes
coupled with methods to enhance neuronal survival would be
required for any long term effective therapy.
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